Cargando…
Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients
INTRODUCTION: NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) is known to be an orphan nuclear receptor that has been characterized as an intracellular immune checkpoint in effector T cells and, therefore, may control tumor development and growth. The prognostic impact of NR...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374721/ https://www.ncbi.nlm.nih.gov/pubmed/36884115 http://dx.doi.org/10.1007/s00432-023-04632-2 |
_version_ | 1785078837153890304 |
---|---|
author | Proppe, L. Jagomast, T. Beume, S. Klapper, L. Gitas, G. Köster, F. Perner, S. Rody, A. Ribbat-Idel, J. Hanker, L. C. |
author_facet | Proppe, L. Jagomast, T. Beume, S. Klapper, L. Gitas, G. Köster, F. Perner, S. Rody, A. Ribbat-Idel, J. Hanker, L. C. |
author_sort | Proppe, L. |
collection | PubMed |
description | INTRODUCTION: NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) is known to be an orphan nuclear receptor that has been characterized as an intracellular immune checkpoint in effector T cells and, therefore, may control tumor development and growth. The prognostic impact of NR2F6 in endometrial cancers is evaluated in this study. MATERIALS AND METHODS: Expression analysis of NR2F6 in 142 endometrial cancer patients was performed by immunohistochemistry of primary paraffin‑embedded tumor samples. Staining intensity of positive tumor cells was automatically assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. RESULTS: Forty five of 116 evaluable samples (38.8%) showed an overexpression of NR2F6. This leads to an improvement of the overall survival (OS) and progression-free survival (PFS). In NR2F6-positive patients, the estimated mean OS was 156.9 months (95% confidence interval (CI) 143.1–170.7) compared to 106.2 months in NR2F6-negative patients (95% CI 86.2–126.3; p = 0.022). The estimated PFS differed by 63 months (152 months (95% CI 135.7–168.4) vs. 88.3 months (95% CI 68.5–108.0), p = 0.002). Furthermore, we found significant associations between NR2F6 positivity, MMR status, and PD1 status. A multivariate analysis suggests NR2F6 to be an independent factor influencing the OS (p = 0.03). CONCLUSION: In this study, we could demonstrate that there is a longer progression-free and overall survival for NR2F6-positive patients with endometrial cancer. We conclude that NR2F6 might play an essential role in endometrial cancers. Further studies are required to validate its prognostic impact. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04632-2. |
format | Online Article Text |
id | pubmed-10374721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103747212023-07-29 Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients Proppe, L. Jagomast, T. Beume, S. Klapper, L. Gitas, G. Köster, F. Perner, S. Rody, A. Ribbat-Idel, J. Hanker, L. C. J Cancer Res Clin Oncol Research INTRODUCTION: NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) is known to be an orphan nuclear receptor that has been characterized as an intracellular immune checkpoint in effector T cells and, therefore, may control tumor development and growth. The prognostic impact of NR2F6 in endometrial cancers is evaluated in this study. MATERIALS AND METHODS: Expression analysis of NR2F6 in 142 endometrial cancer patients was performed by immunohistochemistry of primary paraffin‑embedded tumor samples. Staining intensity of positive tumor cells was automatically assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival. RESULTS: Forty five of 116 evaluable samples (38.8%) showed an overexpression of NR2F6. This leads to an improvement of the overall survival (OS) and progression-free survival (PFS). In NR2F6-positive patients, the estimated mean OS was 156.9 months (95% confidence interval (CI) 143.1–170.7) compared to 106.2 months in NR2F6-negative patients (95% CI 86.2–126.3; p = 0.022). The estimated PFS differed by 63 months (152 months (95% CI 135.7–168.4) vs. 88.3 months (95% CI 68.5–108.0), p = 0.002). Furthermore, we found significant associations between NR2F6 positivity, MMR status, and PD1 status. A multivariate analysis suggests NR2F6 to be an independent factor influencing the OS (p = 0.03). CONCLUSION: In this study, we could demonstrate that there is a longer progression-free and overall survival for NR2F6-positive patients with endometrial cancer. We conclude that NR2F6 might play an essential role in endometrial cancers. Further studies are required to validate its prognostic impact. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-04632-2. Springer Berlin Heidelberg 2023-03-08 2023 /pmc/articles/PMC10374721/ /pubmed/36884115 http://dx.doi.org/10.1007/s00432-023-04632-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Proppe, L. Jagomast, T. Beume, S. Klapper, L. Gitas, G. Köster, F. Perner, S. Rody, A. Ribbat-Idel, J. Hanker, L. C. Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients |
title | Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients |
title_full | Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients |
title_fullStr | Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients |
title_full_unstemmed | Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients |
title_short | Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients |
title_sort | overexpression of the orphan nuclear receptor nr2f6 is associated with improved survival across molecular subgroups in endometrial cancer patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374721/ https://www.ncbi.nlm.nih.gov/pubmed/36884115 http://dx.doi.org/10.1007/s00432-023-04632-2 |
work_keys_str_mv | AT proppel overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT jagomastt overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT beumes overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT klapperl overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT gitasg overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT kosterf overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT perners overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT rodya overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT ribbatidelj overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients AT hankerlc overexpressionoftheorphannuclearreceptornr2f6isassociatedwithimprovedsurvivalacrossmolecularsubgroupsinendometrialcancerpatients |